<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764374</url>
  </required_header>
  <id_info>
    <org_study_id>443-CL-501</org_study_id>
    <nct_id>NCT00764374</nct_id>
  </id_info>
  <brief_title>A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia</brief_title>
  <official_title>A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the safety and efficacy of Z-338 (YM443) after long-term administration in
      patients with functional dyspepsia, and also to examine the pattern of long-term
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's global assessment</measure>
    <time_frame>Every week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disappearance rate of symptoms</measure>
    <time_frame>Every week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests, resting</measure>
    <time_frame>At 0, 4, 12, 24, 36, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>At 0, 24 and 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM443</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Z-338</other_name>
    <other_name>acotiamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient showing at least one of the following 4 symptoms from more than 6 months
             before obtaining consent

               -  postprandial fullness

               -  early satiation

               -  upper abdominal pain

               -  upper abdominal discomfort

          -  Patient showing at least 2 of the 8 symptoms shown below repeatedly from 3 months
             before obtaining consent (At least one symptom of either postprandial fullness or
             early satiation should be included.)

          -  Patient showing either postprandial fullness, bloating in the upper abdomen, or early
             satiation as the major complaint among the 8 symptoms shown below at the time of
             obtaining consent

               -  upper abdominal pain

               -  upper abdominal discomfort

               -  postprandial fullness

               -  bloating in the upper abdomen

               -  early satiation

               -  nausea

               -  vomiting

               -  belching

          -  Outpatient

        Exclusion Criteria:

          -  Patient showing symptoms of organic disease (reflux esophagitis, erosion, ulceration,
             esophageal hiatal hernia, bleeding, malignant tumor, Barrett's esophagus) when upper
             gastrointestinal endoscopy is performed within 24 weeks before obtaining consent

          -  Patient showing heartburn within 12 weeks before obtaining consent

          -  Patient complicated by irritable bowel syndrome

          -  Patient complicated by diabetes mellitus requiring medication

          -  Patient complicated by severe anxiety disorder with some problems in interpersonal
             relationships or social life

          -  Patient complicated by depression (including suspected cases) or sleep disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch.jsp</url>
    <description>Link to Results on JAPIC - enter 140642 in the JapicCTI-RNo. field (Japanese record)</description>
  </link>
  <reference>
    <citation>Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261-8. doi: 10.1159/000332404. Epub 2011 Sep 21.</citation>
    <PMID>21934307</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM443</keyword>
  <keyword>Z-338</keyword>
  <keyword>Acotiamide</keyword>
  <keyword>Rome III</keyword>
  <keyword>Signs and symptoms, digestive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

